Company profile: Neurocrine Biosciences
1.1 - Company Overview
Company description
- Provider of therapies for neurological and endocrine-related diseases, including FDA-approved Ingrezza (valbenazine) for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa and Oriahnn (commercialized by AbbVie) for endometriosis pain and heavy menstrual bleeding associated with uterine fibroids; and investigational Crinecerfont for congenital adrenal hyperplasia due to 21-hydroxylase deficiency, NBI-1065890 (VMAT2 inhibitor), and NBI-1065845 (AMPA potentiator).
Products and services
- Ingrezza (valbenazine): FDA-approved VMAT2 inhibitor indicated for treatment of tardive dyskinesia and chorea associated with Huntington's disease
- Oriahnn (elagolix, estradiol, norethindrone acetate): Combination therapy for managing heavy menstrual bleeding associated with uterine fibroids, commercialized by AbbVie
- Orilissa (elagolix): Medication developed for the management of moderate to severe endometriosis pain, commercialized by AbbVie
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Neurocrine Biosciences
MRM Health
HQ: Belgium
Website
- Description: Provider of microbiome-based therapeutics and development platforms, including the CORAL platform to design optimized microbial consortia, SHIME simulator of the human gut, and Optimized Consortia therapeutics. Offers clinical programs in inflammatory bowel diseases (Ulcerative Colitis, Pouchitis) with MH002, and preclinical programs in CNS, metabolic (Type 2 Diabetes, NAFLD/NASH) and auto-immune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MRM Health company profile →
InfaCare
HQ: United States
Website
- Description: Provider of pharmaceuticals for neonatal and pediatric patients, addressing unmet needs in autoimmune and rare diseases across specialty areas including neurology, rheumatology, nephrology, pulmonology, immunotherapy, and neonatal respiratory critical care.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InfaCare company profile →
Genfit
HQ: France
Website
- Description: Provider of innovative therapeutic and diagnostic solutions for metabolic and liver-related diseases, dedicated to discovery and development in areas with considerable unmet medical needs where approved treatments are lacking; a late-stage biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genfit company profile →
MetaVia Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage multimodal disease-modifying therapies, including DA-1241, an oral GPR119 agonist in Phase 2a for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and DA-1726, a once-weekly dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity, with a Phase 1 clinical trial expected to begin in 2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaVia Therapeutics company profile →
OrsoBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for severe metabolic disorders, including TLC-3595 (selective ACC2 inhibitor) to improve insulin sensitivity in type 2 diabetes; TLC-2716 (liver-targeted LXR inverse agonist) to lower plasma triglycerides and cholesterol in severe dyslipidemias; mitochondrial protonophores (TLC-6740, TLC-1235) to increase energy expenditure; and an ACMSD inhibitor to augment NAD+ and mitochondrial function in liver/kidney dysfunction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OrsoBio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Neurocrine Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Neurocrine Biosciences
2.2 - Growth funds investing in similar companies to Neurocrine Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Neurocrine Biosciences
4.2 - Public trading comparable groups for Neurocrine Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →